Liquidia Corporation
LQDA
Pozycja w akcjach
#4681
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating... Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Cena akcji
$35.98
Kapitalizacja rynkowa
$3.22B
Zmiana (1 dzień)
5.41%
Zmiana (1 rok)
47.20%
Kraj
US
Handel Liquidia Corporation (LQDA)
Kategoria
Healthcare
Wskaźnik P/B dla Liquidia Corporation (LQDA)
Wskaźnik P/B na dzień October 2026 TTM: 15.46
Według najnowszych raportów finansowych i ceny akcji Liquidia Corporation, obecny wskaźnik P/B (TTM) wynosi 15.46. Na koniec 2023 wynosił 16.53.
Historia wskaźnika P/B dla Liquidia Corporation od 2016 do 2026
Wskaźnik P/B na koniec każdego roku
| Rok | Wskaźnik P/B | Zmień |
|---|---|---|
| 2026 (TTM) | 15.46 | 29.07% |
| 2024 | 11.98 | -27.55% |
| 2023 | 16.53 | 284.98% |
| 2022 | 4.29 | -649.51% |
| 2021 | -0.78 | -155.57% |
| 2020 | 1.41 | -37.80% |
| 2019 | 2.26 | -72.77% |
| 2018 | 8.30 | -393.49% |
| 2017 | -2.83 | -45.85% |
| 2016 | -5.22 | 0.00% |
Wskaźnik P/B dla podobnych firm lub konkurentów
| Firma | Wskaźnik P/B | Różnica wskaźnika P/B | Kraj |
|---|---|---|---|
| 3.8424 | -75.15% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 17.3539 | 12.24% |
US
|
